CDT Equity Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand CDT Equity Inc.’s performance. My goal is to break down their complex filings into simple terms so you can decide if this company fits your portfolio.

1. What does this company do?

CDT Equity Inc. is a biotech firm developing two main drugs. The first, AZD1656, is an oral pill being tested for autoimmune issues like rheumatoid arthritis and diabetes complications. The second, AZD5904, is a treatment for male infertility. Because the company is still in the research phase, it makes no money from product sales. Their business model depends on hitting clinical milestones to make their drugs valuable enough to license, partner, or sell to a larger company.

2. Financial performance: "Survival" mode

The company is in a heavy-spending phase. For the year ending December 31, 2025, they lost about $42.5 million, mostly on research and administrative costs. They rely entirely on outside funding to stay afloat.

Investors should note the company’s share price has struggled. Between 2023 and early 2026, they performed several reverse stock splits—1-for-100, 1-for-15, 1-for-8, and 1-for-25. They did this to keep their share price above $1.00, which is required to stay listed on the Nasdaq. While these moves prevented delisting, they highlight the extreme volatility and loss of value shareholders have faced over the last two years.

3. Major wins and challenges

• Wins: The company has successfully raised money despite its financial struggles. In early 2026, they secured $12 million through a deal with Sarborg Limited. This cash is essential to keep their clinical trials running.
• Challenges: The company is stuck in a "dilution spiral." Because they have no revenue, they frequently issue new shares or debt to pay the bills. In the last three years, the total number of shares has grown by over 400%. This means your ownership percentage and voting power have been significantly reduced.

4. Financial health

The company’s finances are fragile. They have about $4.8 million in cash, which management expects will only last until the third quarter of 2026. They must raise more money soon. If their drug trials fail, they may struggle to find new investors, putting the company at risk of going out of business.

5. Key risks

The biggest risk is their lack of cash. They spend money faster than they bring it in, requiring constant fundraising. If regulators demand more expensive testing, their cash will disappear quickly. Also, their reliance on debt creates a "debt overhang." Because investors expect more shares to be issued later, the stock price often struggles to rise.

6. Future outlook

The company is in survival mode, focused entirely on their next round of clinical data. They are cutting costs wherever possible to prioritize their trials. Success is "all or nothing": either the drugs work and lead to a buyout, or the company will need more dilutive funding or face bankruptcy.

Final Investor Takeaway: This is a high-risk, early-stage company. It is not a stable, dividend-paying investment. If you are considering an investment, ask yourself if you are comfortable with a speculative bet that depends entirely on the company turning research into a successful product before their cash runs out. If you prefer companies with established revenue and lower volatility, this may not be the right fit for your portfolio.